Melanoma | Clinical

Dendritic Cell Vaccine Shows Long-Term Survival Benefit in High-Risk Melanoma

August 06, 2020

The final data of a personalized tumor lysate, particle-loaded, dendritic cell vaccine demonstrated that patients with stage III or IV melanoma with high-risk of recurrence after complete surgical resection had better survival benefit and disease-free survival rate with the vaccine over placebo, according to a press release from Elios Therapeutics.

FDA Approves Atezolizumab Triplet Regimen for Treatment of Advanced BRAF-Mutant Melanoma

July 30, 2020

The FDA granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600E-mutated advanced melanoma.

FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma

July 27, 2020

The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

July 26, 2020

A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.

Tweet Chat Recap: Using Immunotherapy and Targeted Therapy for BRAF-Mutant Metastatic Melanoma

July 23, 2020

In an interview with Targeted Oncology, following the tweet chat, Shoushtari highlighted the key takeaways from the tweet chat discussion and spoke to how he would make his own treatment decisions for this patient scenario.

Investigators Present Updated Results of the OpACIN Trial for Melanoma

July 21, 2020

Christian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.

Pembrolizumab Shows Long-Term Benefit in Advanced Melanoma Subgroups

July 17, 2020

A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.

Novel PKC Inhibitor Trial to Expand Its Cohort of Patients With Solid Tumors

July 17, 2020

The phase 2 basket arm trial of IDE196 in patients with solid tumors harboring GNAQ or GNA11 hotspot mutations has met its clinical protocol criteria for cohort expansion.

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

June 27, 2020

In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.

Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma

June 23, 2020

Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.